智通财经APP讯，丽珠医药(01513)公布2024年业绩，营业收入约118.12亿元，同比减少4.97%;归属于公司股东的净利润约20.61亿元，同比增长5.5%。基本每股收益2.24元，拟每 10 股派发现金股利 11.00 元。
公司在商业化、生产运营、创新研发及双向许可等多维度推进国际化战略。随着公司出口业务不断深耕，报告期内公司实现海外收入 17.24 亿元，约占营业总收入的 14.59%，同比增长 9.69%。
其中收入方面影响因素主要为：化学制剂领域，重点产品注射用艾普拉唑钠，受国家医保谈判降价影响，销售收入有所下滑;注射用伏立康唑中标第八批国家药品集中采购、雷贝拉唑钠肠溶胶囊被列入第九批国家药品集中采购目录，相关集采政策正式执行以来，其销售收入同比下降;中药制剂领域，抗病毒颗粒产品在 2024 年的销售收入同比下降，主要由于 2023 年新冠以及持续的流感，使得抗病毒颗粒的市场需求大幅增加，形成了较高的销售基数，而在 2024 年市场需求回落;同时参芪扶正注射液受益于医保目录癌种解限，同比有所增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.